Goldman Sachs Maintains Neutral Rating on PSS World Medical

According to a research report, Goldman Sachs recently attended PSS World Medical's PSSI investor day in New York where PSSI provided an positive three year plan. Following investor day, Goldman Sachs has maintained a $29.00 price target and a Neutral rating on PSSI. In the report, Goldman Sachs said, "On the whole, we are encouraged by PSS's continued commitment to margin expansion through its various internal initiatives, most significantly the private label opportunity where there seems to be an aggressive plan to enter new categories." PSSI closed yesterday at $29.08.